Quinolone-Containing Therapies in the Eradication of Helicobacter pylori

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Chuah, Seng Kee ^a   Tai, Wei Chen ^a   Lee, Chen Hsiang ^a   Liang, Chih Ming ^a   Hu, Tsung Hui ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; DISEASE ERADICATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; MICROBIOLOGY; PHYSIOLOGY;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

DISEASE ERADICATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; QUINOLONES; TUBERCULOSIS;

EID: 84935861057     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/151543     Document Type: Review

References (53)

1. Y. Matsumoto, I. Miki, N. Aoyama et al., "Levofloxacin-versus metronidazole-based rescue therapy for H. pylori infection in Japan, " Digestive and Liver Disease, vol. 37, no. 11, pp. 821-825, 2005.
2. S. K. Chuah, F. W. Tsay, P. I. Hsu, and D. C. Wu, "A new look at anti-Helicobacter pylori therapy, " World Journal of Gastroenterology, vol. 17, no. 35, pp. 3971-3975, 2011.
3. W. D. Chey and B. C. Y. Wong, "AmericanCollege of Gastroenterology guideline on the management of Helicobacter pylori infection, " The American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808-1825, 2007.
4. K. M. Fock, P. Katelaris, K. Sugano et al., "Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection, " Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587-1600, 2009.
5. P. Malfertheiner, F. Megraud, C. A. OMorain et al., "Management of Helicobacter pylori infection-the Maastricht IV/Florence consensus report, " Gut, vol. 61, no. 5, pp. 646-664, 2012.
6. S. K. Chuah, P. I. Hsu, K. C. Chang et al., "Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori, " Helicobacter, vol. 17, no. 3, pp. 216-223, 2012.
7. S. K. Chuah, W. C. Tai, P. I. Hsu et al., "The efficacy of secondline anti-Helicobacter pylori therapy using an extended 14-days'levofloxacin/amoxicillin/protonpump inhibitors-a pilot study, " Helicobacter, vol. 17, pp. 374-381, 2012.
8. A. de Sarro and G. de Sarro, "Adverse reactions to fluoroquinolones: an overview on mechanistic aspects, " Current Medicinal Chemistry, vol. 8, no. 4, pp. 371-384, 2001.
9. M. Tanaka, E. Isogai, H. Isogai et al., "Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori, " Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 1039-1040, 2002.
10. K. L. Goh and P. Navaratnam, "High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics inMalaysia, " Helicobacter, vol. 16, no. 3, pp. 241-245, 2011.
11. K. Murakami, T. Furuta, T. Ando et al., "Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan, " Journal of Gastroenterology, vol. 48, no. 10, pp. 1128-1135, 2013.
12. A. Robicsek, G. A. Jacoby, and D. C. Hooper, "The worldwide emergence of plasmid-mediated quinolone resistance, " The Lancet Infectious Diseases, vol. 6, no. 10, pp. 629-640, 2006.
13. P. Su, Y. Li, H. Li et al., "Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China, " Helicobacter, vol. 18, no. 4, pp. 274-279, 2013.
14. T. T. Binh, S. Shiota, L. T. Nguyen et al., "The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam, " Journal of Clinical Gastroenterology, vol. 47, no. 3, pp. 233-238, 2013.
15. S. Rajper, E. Khan, Z. Ahmad, S. M. Z. Alam, A. Akbar, and R. Hasan, "Macrolide and fluoroquinolone resistance in Helicobacter pylori isolates: an experience at a tertiary care centre in Pakistan, " Journal of the Pakistan Medical Association, vol. 62, no. 11, pp. 1140-1144, 2012.
16. N. Wueppenhorst, H. Stueger, M. Kist, and E. Glocker, "High secondary resistance to quinolones in German Helicobacter pylori clinical isolates, " Journal of Antimicrobial Chemotherapy, vol. 68, no. 7, pp. 1562-1566, 2013.
17. N. Almeida, J. M. Romaozinho, M. M. Donato et al., "Helicobacter pylori antimicrobial resistance rates in the central region of Portugal, " Clinical Microbiology and Infection, 2014.
18. A. H. Tveit, M. G. Bruce, D. L. Bruden et al., "Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska native persons from 2000 to 2008, " Journal of Clinical Microbiology, vol. 49, no. 10, pp. 3638-3643, 2011.
19. J. N. Eisig, F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, J. P. P. Moraes-Filho, and J. Pedrazzoli Jr., "Helicobacter pylori antibiotic resistance in Brazil: Clarithromycin is still a good option, " Arquivos de Gastroenterologia, vol. 48, no. 4, pp. 261-264, 2011.
20. W. C. Tai, C. H. Lee, and S. S. Chiou, "The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication, " PLoS ONE, vol. 9, no. 8, Article ID e105822, 2014.
21. E. R. Greenberg, G. L. Anderson, D. R. Morgan et al., "14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial, " The Lancet, vol. 378, no. 9790, pp. 507-514, 2011.
22. L. Laine, R. Hunt, H. EI-Zimaity, B. Nguyen, M. Osato, and J. Spenard, "Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradicationof Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial, "The American Journal of Gastroenterology, vol. 98, no. 3, pp. 562-567, 2003.
23. D. Vaira, A. Zullo, N. Vakil et al., "Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial, " Annals of Internal Medicine, vol. 146, no. 8, pp. 556-563, 2007.
24. J. M. Liou, C. C. Chen, M. J. Chen et al., "Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre , open-label, randomized trial, " The Lancet, vol. 381, pp. 205-213, 2013.
25. A. Zullo, L. Gatta, V. de Francesco et al., "High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study, " Alimentary Pharmacology and Therapeutics, vol. 21, no. 12, pp. 1419-1424, 2005.
26. H. Seddik, S. Ahid, T. ElAdioui et al., "Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study, " European Journal of Clinical Pharmacology, vol. 69, no. 9, pp. 1709-1715, 2013.
27. K. S. Liu, I. F. Hung, W. K. Seto et al., "Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial, " Gut, vol. 63, no. 9, pp. 1410-1415, 2014.
28. J. S. Kim, B. W. Kim, J. H. Ham et al., "Sequential therapy for Helicobacter pylori infection in Korea: systematic review and meta-analysis, " Gut Liver, vol. 7, pp. 546-551, 2013.
29. H. Fakheri, T. Taghvaei, V. Hosseini, and Z. Bari, "Acomparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in iran: a randomized clinical trial, " Helicobacter, vol. 17, no. 1, pp. 43-48, 2012.
30. N. Sirimontaporn, D. Thong-Ngam, S. Tumwasorn, and V. Mahachai, "Ten-day sequential therapy of Helicobacter pylori infection in thailand, "TheAmerican Journal ofGastroenterology, vol. 105, no. 5, pp. 1071-1075, 2010.
31. D. C. Wu, P. I. Hsu, J. Y. Wu et al., "Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection, " Clinical Gastroenterology and Hepatology, vol. 8, pp. 36-41, 2010.
32. A. S. Essa, J. R. Kramer, D. Y. Graham, and G. Treiber, "Metaanalysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication, " Helicobacter, vol. 14, no. 2, pp. 109-118, 2009.
33. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, "Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days, " Helicobacter, vol. 16, no. 2, pp. 139-145, 2011.
34. T. S. Wu, H. M. Hu, F. C. Kuo, and C. H. Kuo, "Eradication of Helicobacter pylori infection, " Kaohsiung Journal of Medical Sciences, vol. 30, pp. 167-172, 2014.
35. M. Berning, S. Krasz, and S. Miehlke, "Review: should quinolones come first in Helicobacter pylori therapy?"Therapeutic Advances in Gastroenterology, vol. 4, no. 2, pp. 103-114, 2011.
36. M. C. Peedikayil, F. I. Alsohaibani, and A. H. Alkhenizan, "Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials, " PLoS ONE, vol. 9, no. 1, Article ID e85620, 2014.
37. S. P. Xiao, M. Gu, and G. X. Zhang, "Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis, " Scandinavian Journal of Gastroenterology, vol. 49, pp. 528-538, 2014.
38. J. Molina-Infante, B. Perez-Gallardo, M. Fernandez-Bermejo et al., "Clinical trial: clarithromycin vs. levofloxacin in firstline triple and sequential regimens for Helicobacter pylori eradication, " Alimentary Pharmacology and Therapeutics, vol. 31, no. 10, pp. 1077-1084, 2010.
39. J. P. Gisbert and F. De LaMorena, "Systematic review andmetaanalysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure, " Alimentary Pharmacology and Therapeutics, vol. 23, no. 1, pp. 35-44, 2006.
40. S. Miehlke, S. Krasz, W. Schneider-Brachert et al., "Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection, " Helicobacter, vol. 16, no. 6, pp. 420-426, 2011.
41. G. Cammarota, A. Martino, G. Pirozzi et al., "High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection, " Alimentary Pharmacology & Therapeutics, vol. 19, no. 7, pp. 789-795, 2004.
42. L. Boyanova, "Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria, " Journal of Medical Microbiology, vol. 58, no. 7, pp. 930-935, 2009.
43. F. Megraud and P. Lehours, "Helicobacter pylori detection and antimicrobial susceptibility testing, " Clinical Microbiology Reviews, vol. 20, no. 2, pp. 280-322, 2007.
44. E. Ierardi, F. Giorgio, G. Losurdo, A. D. Leo, and M. Principi, "As the increase in antibiotic resistances could change the treatment of helicobacter pylori infection: itwill be amatter of geography?" World Journal of Gastroenterology, vol. 19, pp. 8168-8180, 2013.
45. J. M. Liou, C. C. Chen, C. Y. Chang et al., "Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: amulticentre clinical trial, " Journal of Antimicrobial Chemotherapy, vol. 68, pp. 450-456, 2013.
46. J. Matsuzaki, H. Suzuki, T. Nishizawa et al., "Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first-and second-line therapies, " AntimicrobialAgents and Chemotherapy, vol. 56, no. 3, pp. 1643-1645, 2012.
47. C. Schabereiter-Gurtner, A. M. Hirschl, B. Dragosics et al., "Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens, " Journal of Clinical Microbiology, vol. 42, no. 10, pp. 4512-4518, 2004.
48. J. M. Liou, C. Y. Chang, W. H. Sheng et al., "Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacinand clarithromycinbased therapies, " Antimicrobial Agents and Chemotherapy, vol. 55, no. 3, pp. 1123-1129, 2011.
49. C. Y. Jeon, A. D. Calver, T. C. Victor, R. M. Warren, S. S. Shin, and M. B. Murray, "Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community, " International Journal of Tuberculosis and Lung Disease, vol. 15, no. 1, pp. 77-83, 2011.
50. R. A. Devasia, A. Blackman, T. Gebretsadik et al., "Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure, " The American Journal of Respiratory and Critical CareMedicine, vol. 180, no. 4, pp. 365-370, 2009.
51. W. C. Tai, T. H. Hu, C. H. Lee, H. H. Chen, C. C. Huang, and S. K. Chuah, "Ano-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan, " Colorectal Disease, vol. 12, no. 7, pp. e114-120, 2010.
52. W. L. Chang, C. Y. Kao, C. T. Wu et al., "Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan, " Helicobacter, vol. 17, no. 3, pp. 210-215, 2012.
53. S. Y. Kim, J. Yim, J. S. Park et al., "Clinical effects of gemifloxacin on the delay of tuberculosis treatment, " Journal of Korean Medical Science, vol. 28, no. 3, pp. 378-382, 2013.